hfCas12Max is a high-fidelity CRISPR nuclease engineered specifically for cell and gene therapy applications. It demonstrates unparalleled precision and efficiency across various models making it the best nuclease for your next CRISPR experiment.

Scientists are seeking novel nuclease alternatives to overcome the entry barrier to developing cell and gene therapies using CRISPR. Enter hfCas12Max, an engineered novel nuclease with a simplified licensing structure. Due to its high fidelity across various models and broad PAM sequence recognition profile, hfCas12Max is the best nuclease for your therapeutic needs.

Key aspects of hfCas12Max this poster closely examines:

  • How it was engineered with a unique platform
  • Demonstrates therapeutic potential with results in mouse models having reduced HBsAg and HBV DNA levels.
  • High editing performance in human primary cells
  • Genome-wide off-target analysis showcasing its minimized off-targets
  • Its ability to edit target sites inaccessible by other nucleases
  • Emphasize the importance of affordable licensing structures in developing therapeutics.

Unlock the potential of hfCas12Max for your research and therapeutic development. Download our detailed poster to explore how this novel nuclease can elevate your cell and gene therapy projects.